



## DEPOSITARY RECEIPTS

### NEW DR ANNOUNCEMENT

May 15, 2015

#### BiondVax Pharmaceuticals Ltd

BiondVax Pharmaceuticals is a biopharmaceutical company based in Israel. The Company is engaged in developing a universal influenza vaccine. The Company's primary product is the Multimeric-001 universal flu vaccine, which has completed two Phase II and two Phase I/II clinical trials to provide multi-season and multi-strain protection against human influenza virus strains, including seasonal and pandemic flu strains. The Company's technology utilizes a combination of conserved epitomes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. The Company maintains exclusive license granted by Yeda Research & Development, the commercial arm of the Weizmann Institute.

<b>DR Name:</b>	BiondVax
<b>Effective Date:</b>	May 15, 2015
<b>Country of Incorporation:</b>	Israel
<b>Exchange:</b>	NASDAQ Stock Market
<b>Type of ADR Program:</b>	Sponsored - Level III
<b>Ticker Symbol:</b>	BVXV
<b>CUSIP Number:</b>	09073Q105
<b>Ratio (DR:ORD):</b>	1 : 40
<b>Underlying Share Description:</b>	Ordinary
<b>Industry Classification:</b>	Pharma. & Biotech.
<b>Custodian(s) :</b>	Bank Hapoalim B.M.

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis  
Adrdesk@bnymellon.com  
Tel: 212 815 2267

#### Hong Kong

Herston Powers  
Vice President  
herston.powers@bnymellon.com  
Tel: 852 2840 9868

#### London

Jacek Jankowski  
DR Broker Liaison Support  
jacek.jankowski@bnymellon.com  
Tel: 442071637427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.